Report Detail
Global Neurodegenerative Diseases Therapeutics Market Insights, Forecast to 2028
- RnM4437182 |
- 09 May, 2022 |
- Global |
- 112 Pages |
- QYResearch |
- Medical Industry
Summary:
Market Analysis and Insights: Global Neurodegenerative Diseases Therapeutics Market
The global Neurodegenerative Diseases Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Multiple Sclerosis Therapeutics accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Child segment is altered to an % CAGR throughout this forecast period.
China Neurodegenerative Diseases Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Neurodegenerative Diseases Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Neurodegenerative Diseases Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Diseases Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Diseases Therapeutics market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Neurodegenerative Diseases Therapeutics market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Neurodegenerative Diseases Therapeutics Breakdown Data by Type
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Neurodegenerative Diseases Therapeutics Breakdown Data by Application
Child
Aldult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Frequently Asked Questions
What factors will challenge the Neurodegenerative Diseases Therapeutics market growth?
Which end-use segment will expand at the fastest CAGR in the Neurodegenerative Diseases Therapeutics market?
Which are the emerging players in the Neurodegenerative Diseases Therapeutics market?
How concentrated is the Neurodegenerative Diseases Therapeutics market?
Which factors are positively contributing to the Neurodegenerative Diseases Therapeutics market growth?
Which are the novel product innovations in the Neurodegenerative Diseases Therapeutics market?
Which product segment will emerge as the most lucrative in the Neurodegenerative Diseases Therapeutics market?
Which factors are increasing the competition in the Neurodegenerative Diseases Therapeutics market?
Which are the strategic measures taken by the Neurodegenerative Diseases Therapeutics industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Neurodegenerative Diseases Therapeutics market in the coming years?
Table of Contents
1 Report Business Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
- 1.2.2 Multiple Sclerosis Therapeutics
- 1.2.3 Alzheimer's Disease Therapeutics
- 1.2.4 Parkinson's Disease Therapeutics
- 1.2.5 Parkinson's Disease Therapeutics
- 1.2.6 Others
- 1.3 Market by Application
- 1.3.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Child
- 1.3.3 Aldult
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2017-2028)
- 2.2 Neurodegenerative Diseases Therapeutics Growth Trends by Region
- 2.2.1 Neurodegenerative Diseases Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2017-2022)
- 2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028)
- 2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
- 2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
- 2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
- 2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
- 2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
- 3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2017-2022)
- 3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2017-2022)
- 3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Neurodegenerative Diseases Therapeutics Revenue
- 3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
- 3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2021
- 3.5 Neurodegenerative Diseases Therapeutics Key Players Head office and Area Served
- 3.6 Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
- 3.7 Date of Enter into Neurodegenerative Diseases Therapeutics Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
- 4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2017-2022)
- 4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
- 5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2017-2022)
- 5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
- 6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
- 6.2 North America Neurodegenerative Diseases Therapeutics Market Size by Type
- 6.2.1 North America Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
- 6.2.2 North America Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
- 6.2.3 North America Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
- 6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Application
- 6.3.1 North America Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
- 6.3.2 North America Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
- 6.3.3 North America Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
- 6.4 North America Neurodegenerative Diseases Therapeutics Market Size by Country
- 6.4.1 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
- 6.4.2 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
- 6.4.3 United States
- 6.4.4 Canada
7 Europe
- 7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
- 7.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Type
- 7.2.1 Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
- 7.2.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
- 7.2.3 Europe Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
- 7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Application
- 7.3.1 Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
- 7.3.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
- 7.3.3 Europe Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
- 7.4 Europe Neurodegenerative Diseases Therapeutics Market Size by Country
- 7.4.1 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
- 7.4.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic Countries
8 Asia-Pacific
- 8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
- 8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Type
- 8.2.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
- 8.2.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
- 8.2.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
- 8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Application
- 8.3.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
- 8.3.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
- 8.3.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
- 8.4 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region
- 8.4.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022)
- 8.4.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2023-2028)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 Southeast Asia
- 8.4.7 India
- 8.4.8 Australia
9 Latin America
- 9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
- 9.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Type
- 9.2.1 Latin America Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
- 9.2.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
- 9.2.3 Latin America Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
- 9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Application
- 9.3.1 Latin America Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
- 9.3.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
- 9.3.3 Latin America Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
- 9.4 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country
- 9.4.1 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
- 9.4.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
- 9.4.3 Mexico
- 9.4.4 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
- 10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type
- 10.2.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
- 10.2.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
- 10.2.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
- 10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application
- 10.3.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
- 10.3.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
- 10.3.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
- 10.4 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country
- 10.4.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
- 10.4.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
- 10.4.3 Turkey
- 10.4.4 Saudi Arabia
- 10.4.5 UAE
11 Key Players Profiles
- 11.1 AB Science SA
- 11.1.1 AB Science SA Company Details
- 11.1.2 AB Science SA Business Overview
- 11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
- 11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.1.5 AB Science SA Recent Developments
- 11.2 AbbVie Inc.
- 11.2.1 AbbVie Inc. Company Details
- 11.2.2 AbbVie Inc. Business Overview
- 11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
- 11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.2.5 AbbVie Inc. Recent Developments
- 11.3 Acadia Pharmaceuticals Inc.
- 11.3.1 Acadia Pharmaceuticals Inc. Company Details
- 11.3.2 Acadia Pharmaceuticals Inc. Business Overview
- 11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
- 11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.3.5 Acadia Pharmaceuticals Inc. Recent Developments
- 11.4 Biogen Inc.
- 11.4.1 Biogen Inc. Company Details
- 11.4.2 Biogen Inc. Business Overview
- 11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
- 11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.4.5 Biogen Inc. Recent Developments
- 11.5 F. Hoffmann La Roche Ltd.
- 11.5.1 F. Hoffmann La Roche Ltd. Company Details
- 11.5.2 F. Hoffmann La Roche Ltd. Business Overview
- 11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
- 11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.5.5 F. Hoffmann La Roche Ltd. Recent Developments
- 11.6 H Lundbeck AS
- 11.6.1 H Lundbeck AS Company Details
- 11.6.2 H Lundbeck AS Business Overview
- 11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
- 11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.6.5 H Lundbeck AS Recent Developments
- 11.7 Mitsubishi Chemical Holdings Corp.
- 11.7.1 Mitsubishi Chemical Holdings Corp. Company Details
- 11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
- 11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
- 11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.7.5 Mitsubishi Chemical Holdings Corp. Recent Developments
- 11.8 Novartis AG
- 11.8.1 Novartis AG Company Details
- 11.8.2 Novartis AG Business Overview
- 11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
- 11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.8.5 Novartis AG Recent Developments
- 11.9 Sanofi
- 11.9.1 Sanofi Company Details
- 11.9.2 Sanofi Business Overview
- 11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
- 11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.9.5 Sanofi Recent Developments
- 11.10 Teva Pharmaceutical Industries Ltd
- 11.10.1 Teva Pharmaceutical Industries Ltd Company Details
- 11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
- 11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
- 11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
- 11.10.5 Teva Pharmaceutical Industries Ltd Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Author Details
Summary:
Get latest Market Research Reports on Neurodegenerative Diseases Therapeutics. Industry analysis & Market Report on Neurodegenerative Diseases Therapeutics is a syndicated market report, published as Global Neurodegenerative Diseases Therapeutics Market Insights, Forecast to 2028. It is complete Research Study and Industry Analysis of Neurodegenerative Diseases Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
